Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $106.45 million. The enterprise value is $150.48 million.
| Market Cap | 106.45M |
| Enterprise Value | 150.48M |
Important Dates
The last earnings date was Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 11.09 million shares outstanding. The number of shares has increased by 31.30% in one year.
| Current Share Class | 11.09M |
| Shares Outstanding | 11.09M |
| Shares Change (YoY) | +31.30% |
| Shares Change (QoQ) | +3.54% |
| Owned by Insiders (%) | 39.78% |
| Owned by Institutions (%) | 29.68% |
| Float | 5.41M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.04 |
| Forward PS | 0.93 |
| PB Ratio | 12.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.46 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.96, with a Debt / Equity ratio of 8.35.
| Current Ratio | 2.96 |
| Quick Ratio | 2.63 |
| Debt / Equity | 8.35 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -2.45 |
Financial Efficiency
Return on equity (ROE) is -778.89% and return on invested capital (ROIC) is -16.13%.
| Return on Equity (ROE) | -778.89% |
| Return on Assets (ROA) | -13.45% |
| Return on Invested Capital (ROIC) | -16.13% |
| Return on Capital Employed (ROCE) | -24.66% |
| Weighted Average Cost of Capital (WACC) | 8.13% |
| Revenue Per Employee | $315,006 |
| Profits Per Employee | -$81,072 |
| Employee Count | 334 |
| Asset Turnover | 1.15 |
| Inventory Turnover | 14.28 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +27.50% in the last 52 weeks. The beta is 0.63, so Biodesix's price volatility has been lower than the market average.
| Beta (5Y) | 0.63 |
| 52-Week Price Change | +27.50% |
| 50-Day Moving Average | 23.58 |
| 200-Day Moving Average | 18.89 |
| Relative Strength Index (RSI) | 25.60 |
| Average Volume (20 Days) | 280,082 |
Short Selling Information
The latest short interest is 210,018, so 1.89% of the outstanding shares have been sold short.
| Short Interest | 210,018 |
| Short Previous Month | 209,504 |
| Short % of Shares Out | 1.89% |
| Short % of Float | 3.89% |
| Short Ratio (days to cover) | 2.28 |
Income Statement
In the last 12 months, Biodesix had revenue of $105.21 million and -$27.08 million in losses. Loss per share was -$2.80.
| Revenue | 105.21M |
| Gross Profit | 86.65M |
| Operating Income | -19.65M |
| Pretax Income | -27.08M |
| Net Income | -27.08M |
| EBITDA | -14.08M |
| EBIT | -19.65M |
| Loss Per Share | -$2.80 |
Balance Sheet
The company has $28.41 million in cash and $72.44 million in debt, with a net cash position of -$44.03 million or -$3.97 per share.
| Cash & Cash Equivalents | 28.41M |
| Total Debt | 72.44M |
| Net Cash | -44.03M |
| Net Cash Per Share | -$3.97 |
| Equity (Book Value) | 8.68M |
| Book Value Per Share | 0.78 |
| Working Capital | 27.89M |
Cash Flow
In the last 12 months, operating cash flow was -$18.16 million and capital expenditures -$919,000, giving a free cash flow of -$19.07 million.
| Operating Cash Flow | -18.16M |
| Capital Expenditures | -919,000 |
| Depreciation & Amortization | 5.57M |
| Net Borrowing | -11,000 |
| Free Cash Flow | -19.07M |
| FCF Per Share | -$1.72 |
Margins
Gross margin is 82.36%, with operating and profit margins of -18.68% and -25.74%.
| Gross Margin | 82.36% |
| Operating Margin | -18.68% |
| Pretax Margin | -25.74% |
| Profit Margin | -25.74% |
| EBITDA Margin | -13.38% |
| EBIT Margin | -18.68% |
| FCF Margin | n/a |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.30% |
| Shareholder Yield | -31.30% |
| Earnings Yield | -29.16% |
| FCF Yield | -17.41% |
Analyst Forecast
The average price target for Biodesix is $32.17, which is 235.10% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $32.17 |
| Price Target Difference | 235.10% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 7 |
| Revenue Growth Forecast (3Y) | 19.38% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
The last stock split was on September 15, 2025. It was a reverse split with a ratio of 1:20.
| Last Split Date | Sep 15, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:20 |
Scores
Biodesix has an Altman Z-Score of -5.96 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.96 |
| Piotroski F-Score | 4 |